

IMI2 - Calls 15 & 16: Rules and procedures



First Name	Last Name	Email	Country	Organization	Which IMI2 - Call 15 & 16 topic(s) are you most interested in?	Briefly, what would you bring to the project in terms of expertise, resources, activities?
Juan	Abolafia	jabolafi@clinic.ub.es	Spain	Fundacio Clinic per a la Recerca Biomedica		
Amélie	Abrantes	amelie.abrantes@u-bordeaux.fr	France	Université de Bordeaux		
ITZIAR	ACHA	iacha@bioef.org	Spain	Fundación Vasca de Innovación e Investigación Sanitarias - BIOEF	All of them	
Petar	Atanasov	petar.atanasov@amaris.com	Spain	Amaris	Blockchain enabled healthcare	Technical expertise on blockchain technology; score knowledge of healthcare nanotechnology
Helena	Azevedo	h.azevedo@qmul.ac.uk	United Kingdom	Queen Mary University of London	5 and 7	
Veerle	Baekelandt	Veerle.Baekelandt@kuleuven.be	Belgium	KU Leuven	Synaptopathy	
Juan Manuel	Báez	jmbaez@pharmamar.com	Spain	Sylentis S.A. (PharmaMar Grupo)	Blockchain enabled healthcare // Digital transformation of clinical trial endpoints	Drug development, preclinical development and clinical trials conducting (Oncology and therapeutic areas), RNA interference.
Edita	Bagdonaite	edita.bagdonaite@mita.lt	Lithuania	Agency for Science, Innovation and Technology		
Ingrid	Balcells	ingrid.balcells@vhir.org	Spain	VHIR		
Alexandra	Bizy	abizy@incliva.es	Spain	INCLIVA		
Katja	Boelcker	k.boelcker@european-biotechnology.r	Germany	Biocom AG	AMR Accelerator Pillar A	Communication, dissemination and project management of EU, IMI and national projects; event/conference planning
Carlos	Boto	csmboto@dodoc.com	Portugal	doDOC - Accelerating the creation of medical products by streamlining R&D, medical communications and regulatory documentation	R&D & regulatory processes	doDOC allows several people to work on the same document at the same time obtaining a full audit-trail of any document.
Willo	Brock	willo.brock@tballiance.org	United States	TB Alliance		
MARTA	BURGOS GONZALEZ	proyectos@parkinsonmadrid.org	Spain	ASOCIACION PARKINSON MADRID	blockchain enable healthcare and digital transformation of clinical trial endpoints	we are a patients' association (more 2000 member) with 56 social and health professionals. Co creation, validation user needs.
Célia	Cabral	celia.cabral@fmed.uc.pt	Portugal	Faculdade de Medicina, Universidade de Coimbra		
Montse	Camprubi	mcamprubi@synapse-managers.com	Spain	SYNPASE Research Management Partners		
Laura	Castaneda	laura@plasmabiotech.com	Spain	Plasmia Biotech SL		Libraries of molecules, expertise in medical chemistry and Drug discovery
Corentin	Chaboud	corentin.chaboud@bioaster.org	France	BIOASTER	AMR Accelerator - Pillar A, B, C (topic 3 and 5)	animal models of infection, omics technologies for new mechanism of actions, data management & analysis,
Marcela	Chavez	vchavez@chuliege.be	Belgium	Liège University Hospital (CHU Liège)	Synaptopathy drug discovery and Platforms enabling Patient-Centric Drug Development	Clinical Trials, Drug discovery, Patient recruitment, Neurological diseases expertise, Advanced Brain Imaging/markers.
Alexandra	Chukas	alexandra.chukas@icm-institute.org	France	ICM	Synaptopathy drug discovery	
Janete	Chung	janete.chung@uis.no	Norway	Stavanger University Hospital		
Daniel	Da Costa	d.dacosta@inoviem.com	France	Inoviem Scientific	Integrated research platforms enabling patientcentric drug development	Unique technological solutions for drug interactome isolation and analysis directly from patient samples

Aniek	Doensen	aniek.doensen@catalyze.nl	Netherlands	Catalyze		
Rafael	Espinosa	rafaelespinosa@rtidi.eu	Spain	RTDI	Blockchain	
Silvia	Farina	silvia.farina@ifom.eu	Italy	IFOM - The FIRC Institute of Molecular Oncology		
Sofia	Fernandes	sofia.fernandes@ucp.pt	Portugal	CREATING HEALTH		
María Emilia	Fernández-Prieto Pérez	mefernandez-prieto@pharmamar.com	Spain	PharmaMar	IMI2-Call15-Topic 1 and IMI2-Call 16- Pillar C	PharmaMar: 30 years of experience in marine biomedicine. PharmaMar's core business is oncology
Mireia	ferri	mferri@Kveloce.com	Spain	Kveloce		
Jose Angel	Freire Astray	freire@clinic.cat	Spain	Fundació Clínic per a la Recerca Biomèdica		
Mireia	Gimenez	mgimenez@leitat.org	Spain	LEITAT	Call 15 and 16	Extensive preclinical models; in depth mechanism of action investigation; biodistribution; organoid technology; Biosensors; NPs.
Maria Julia	Gomes de Moura	mariajuliamoura@ics.lisboa.ucp.pt	Portugal	UCP	Emerging translational safety technologies and tools for interrogating human immuno-biology	
Fernando	Gómez Hermoso	gohef81@gmail.com	Spain	Research Foundation HM Hospitales	Overview on IMI2	Management of R&D programs, Outreach and Training activities, Promotion and Technology Transfer, Scientific database
Simone	Gottardi	simone.gottardi@catalyze.nl	Netherlands	Catalyze B.V.		
Laura	Griestop	l.griestop@european-biotechnology.net	Germany	BIOCOM AG		
Panagiotis	Ignatiadis	ignatiadis@help-forward.gr	Greece	Praxi Network		
Laura	Isús	laura.isus@genomcore.com	Spain	Genomcore	Blockchain enabled healthcare	
IRENE	JORGE	irene.jorge@upc.edu	Spain	UPC		
Maria Dolores	Julian	drmdjulian@hotmail.com	Spain	Freelance		
Bas	Kremer	bas.kremer@tno.nl	Netherlands	TNO		immune health tooling, data analytics/AI, microbiome, immunology network
Hester	Kuipers	hkuipers@iavi.org	Netherlands	IAVI	Antimicrobial Resistance	Relevant technologies, product development expertise, project management, communications
nekane	Iarburu	niarburu@vicomtech.org	Spain	Vicomtech		
Christina	Lercher	christina.lercher@standort-tirol.at	Austria	Standortagentur Tirol		
Iraida	Loinaz	iloinaz@cidetec.es	Spain	Fundación CIDETEC	Antibiotic nanoformulation	Small nanoparticles (25 nm), high diffusion capability, non-mucoadhesive, lung delivery. GMP pilot plant
Gustavo	Lopez	gustavo.lopezrazola@chemogroup.co	Spain	Chemo Group		
Anu	Mahalingashetty	anu.mahalingashetty@tballiance.org	United States	TB Alliance		
Julio	Mancera	julio.mancera@cloverbiosoft.com	Spain	Clover Biosoft	Antimicrobial resistance (AMR) accelerator programme	Wide experience in MS MALDI-TOF and bioinformatics
Giulia	MANINA	giulia.manina@pasteur.fr	France	Institut Pasteur		
Idoia	Mínguez	iminguez@grupoadigest.com	Spain	Adigest / Incotec	Both	I would like to learn about rules and procedures of this call
Maria	Monsalve	m.monsalve@csic.es	Spain	Instituto de Investigaciones Biomédicas Alberto Sols	Integrated research platforms enabling patient-centric drug development.	Early Identification of drug induced changes in metabolism that predict long term outcomes
María	Moreno	maria.moreno@innovandumhealth.co	Spain	INNOVANDUM HEALTH		
Astrid	Mork-Jansson	astrid.mork-jansson@uis.no	Norway	University of Stavanger		Biochemistry, molecular biology, blood brain barrier, epilepsy, exosomes in therapeutics
Catarina	Neves	catarinamneves@med.up.pt	Portugal	CINTESIS-FMUP	all topics	
Vera	Nies	veranies@gmail.com	Netherlands	Lygature	Digital transformation of clinical trial endpoints	

Ute	Panzenboeck	ute.panzenboeck@medunigraz.at	Austria	Medical University of Graz	Immunology	Cell biology, primary cell models, expertise in cholesterol and lipoprotein metabolism, nuclear receptor signaling, β -amyloid
Markus	Pasterk	admin.dir@bbmri-eric.eu	Austria	BBMRI-ERIC		
Olga	Pervushina	pervushina_olga@yahoo.com	Germany	Medical Grants Pervushina&Partners		Monitoring of funding opportunities
Anett	Pfeiffer	a.pfeiffer@eurice.eu	Germany	EURICE GmbH		Expertise in collaborative project management and exploitation management (management partner in running IMI projects)
Laura	Planells	laura.planells@vhir.org	Spain	VHIR		
Vaclovas	Radvilas	vaclovas.radvilas@zeclinics.com	Spain	ZeClinics SL	Translational safety technologies for human immuno-biology & Translational platforms for synaptopathy drug discovery	Generation of disease models (using zebrafish) to address the efficacy and safety of novel drugs immuno-biology and synaptopathy
Angel Manuel	Rafael	arafael@idimas.es	Spain	IDimas Gestión	Blockchain enabled healthcare	Project management, consortium composed of public university and SME and big companies related to the topic
Santiago	Ramon Garcia	santiramon@unizar.es	Spain	Research & Development Agency of Aragon (ARAID) Foundation	Call 15 (topic 8 Pillar B) call 16 and Pillar C (topic 3)	Drug profiling, combination studies, in vitro and in vivo models, PKPD modeling, mode of action elucidation studies, time-lapse
Ester	Rodriguez	erodriguez@cmrb.eu	Spain	Center of Regenerative Medicine in Barcelona (CMRB)		Regenerative medicine, stem cells, organoids
Maria	Saarela	maria.saarela@imibic.org	Spain	IMIBIC	AMR mainly	patient recruitment
Sònia	Sagristà	ssagrista@idibell.cat	Spain	IDIBELL		
Yolanda	Sastre FOnt	ysastre@clinic.cat	Spain	Fundació Clinic per a la Recerca Biomèdica	All topics in which Health/Clinical Professionals are involved (Universitary Hospital highly focused on research and Innovation)	Patients, Recruitment of subjects, clinical know-how, Clinical Trials expertise, integrated CTU, central hospital expertise...
Ashwini	Sathnur	ashwiniashis@yahoo.com	India	United Nations Development Programme	Emerging translational safety technologies and tools for interrogating human immuno-biology; Blockchain enabled healthcare;	Inclusive Development
Anna	Segre	anna.segre@csp-st.it	Italy	CSP-ST		
Arnau	Sellares	arnau.sellares@madeofgenes.com	Spain	Genomcore	Blockchain enabled healthcare	Security, privacy, transactional solutions, informed consent management
Sorin	STIRCU	sorin.stircu@ehealthline.com	United States	E*HealthLine	All	
Daniel	Vander Vorst	dvandervorst@vicomtech.org	Spain	Vicomtech		
Tom	Vercruysse	tom.vercruysse@kuleuven.be	Belgium	KU Leuven		